Zydus-Formycon Keytruda Biosimilar FYB206 Accepted For USFDA Review

The proposed pembrolizumab biosimilar could receive a USFDA decision by Q3 2027, potentially expanding access to cancer treatment in North AmericaZydus Lifesciences and Germany-based Formycon AG have received US Food and Drug Administration (USFDA) acceptance for review of the Biologics License App…